Natural Sciences
Life Sciences
Scientific Computing
Life Science

Eric Fischer, Medical School, Harvard, Boston, USA

ZMBH, Seminar room 001, ground floor, Im Neuenheimer Feld 282

Ingrid Schmid

Small molecules that induce protein degradation through ligase-mediated ubiquitination have shown considerable promise as a new pharmacological modality. Work on the mechanism of action of thalidomide and related IMiDs provided the clinical proof of concept, while significant progress has recently been made towards chemically induced targeted protein degradation using heterobifunctional small molecule ligands (often referred to as degraders or PROTACs for PROteolysis-TArgeting Chimeras). However, we currently lack a detailed understanding of the molecular basis for target recruitment and selectivity, which is critically required to enable rational design of such molecules. We will present recent work towards a better understanding of the molecular principles that govern neo-substrate recruitment, and its application to the development of small molecule degraders

Event data:
Import event data into Outlook Calendar